Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Conditions:   Colorectal Cancer;   Metastatic Colorectal Cancer Interventions:   Drug: Onvansertib;   Drug: FOLFIRI;   Drug: Bevacizumab Sponsor:   Cardiff Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials